News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Novartis International AG Painkiller Prexige Gets “Not Approvable” Letter in U.S.
September 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Sept 27 (Reuters) - U.S. regulators have rejected Novartis AG's (NOVN.VX: Quote, Profile, Research) Prexige painkiller, a move that had been expected after Australia withdrew the drug on concerns over liver side-effects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
January 7, 2026
·
2 min read
·
Heather McKenzie
Vaccines
Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule
January 6, 2026
·
3 min read
·
Dan Samorodnitsky
FDA
FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025
January 6, 2026
·
3 min read
·
Heather McKenzie
FDA
Calls for Leadership Stability and Rare Disease Follow-Through at FDA in 2026
January 5, 2026
·
9 min read
·
Tristan Manalac